QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

$23.32
0.00 (0.00%)
(As of 02/22/2024 ET)
Today's Range
$23.32
$23.32
50-Day Range
$23.15
$27.00
52-Week Range
$18.35
$27.00
Volume
N/A
Average Volume
23 shs
Market Capitalization
N/A
P/E Ratio
32.39
Dividend Yield
N/A
Price Target
N/A

BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

BIOVF Stock News Headlines

Swedish Orphan Biovitrum AB (publ) (SWOBY)
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Invitation: Sobi's Q4 and FY 2023 report
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Swedish Orphan Biovitrum AB BIOVF
Sobi has completed the issuances of series C shares
Reminder: Invitation: Sobi's Q3 2023 report
Invitation: Sobi's Q3 2023 report
Sobi KOL investor event: the journey for Vonjo®
Invitation: Sobi's Q2 2023 report
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

Net Income
$227.10 million
Pretax Margin
16.72%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Cash Flow
$1.88 per share
Book Value
$8.91 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.51

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 59)
    CEO & President
    Comp: $22.78M
  • Mr. Henrik Stenqvist (Age 57)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 55)
    General Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 44)
    Head of Strategy & Corporate Development
  • Ms. Lena Bjurner (Age 56)
    Head of Human Resources
  • Mr. Armin Reininger M.D. (Age 67)
    Ph.D., Senior Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 57)
    Head of International
  • Mr. Sofiane Fahmy (Age 52)
    Head of Europe
  • Mr. Duane H. Barnes (Age 64)
    Head of North America
  • Mr. Mahmood Ladha (Age 60)
    Head of Strategic Transformation Operations














BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings
or view top-rated stocks.

How have BIOVF shares performed in 2024?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of the year. Since then, BIOVF stock has decreased by 11.2% and is now trading at $23.32.
View the best growth stocks for 2024 here
.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 456,200 shares, a decline of 17.1% from the December 31st total of 550,100 shares. Based on an average trading volume of 300 shares, the days-to-cover ratio is currently 1,520.7 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest
.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) issued its quarterly earnings data on Thursday, February, 8th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.56 by $0.26. The firm earned $643.39 million during the quarter, compared to analyst estimates of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 9.20% and a net margin of 10.95%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 2/22/2024 by MarketBeat.com Staff